The White House is planning to officially launch its direct-to-consumer, lower-cost drug platform TrumpRx Thursday evening, unveiling the results of President Trump’s “most favored nation” (MFN) drug pricing policy.
The Trump administration announced plans to launch its TrumpRx website in September, with administration officials saying at the time that the platform would cut out intermediaries and offer drugs “often at full MFN, and always at lower prices than currently available.” Health officials said at the time that the platform would launch sometime in early 2026.
White House press secretary Karoline Leavitt confirmed the news Thursday in a post on social platform X.
“TONIGHT AT 7PM: President Trump, Dr. [Mehmet] Oz, and National Design Studio Director Joe Gebbia will be officially unveiling TrumpRx — a state of the art website for Americans consumers to purchase low cost prescription drugs,” she wrote. “This historic announcement will save millions of Americans money.”
A senior administration official previously specified that “the government is not getting into the drug distribution business.”
“Rather, this is a convening site where Americans can come and know that this is a place where they can go direct-to-consumer and access the lowest prices available through the President’s MFN initiative,” the official added.
The platform will offer some of the medications manufactured by companies that have entered into MFN pricing agreements with the administration. These include drugmakers like Pfizer, AstraZeneca, Eli Lilly, Novo Nordisk, Amgen, Boehringer Ingelheim, Bristol Myers Squibb, Genentech, Gilead Sciences, GlaxoSmithKline, Merck & Co., Novartis and Sanofi.
Many of these companies faced steep Section 232 tariffs by the Trump administration, which granted them “grace periods” after they agreed to MFN deals.
The administration has offered some hints at what the TrumpRx.gov platform will look like. Injectable and infusion products, like Novo Nordisk’s star product Ozempic, will not be available on the website as an official said it would not be “clinically appropriate” to sell those types of products without a provider present.
Health officials have also indicated the platform will not accept insurance, seeking to bypass those companies.
https://thehill.com/policy/healthcare/5724285-white-house-trumprx-launch-most-favored-nation/
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.